{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:52:17Z","timestamp":1794027137730,"version":"4.8.0"},"reference-count":122,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR)\u2013natural killer (NK) cells represent a novel cell therapy platform distinguished from CAR T cells by their more favorable safety profile, easier off-the-shelf allogeneic manufacturing and consequent scalability, and their innate cytotoxicity without needing previous sensitization. CAR-NK cells derived from a variety of sources have been used against hematologic malignancies in several clinical trials, showing significant therapeutic responses and efficacy without severe adverse effects. Limitations that are being addressed in CAR-NK cell therapy include challenges regarding NK cell persistence in vivo, metabolic bottlenecks, and tumor-coopted immunosuppressive mechanisms that induce NK cell exhaustion. This review synthesizes current trends and innovations in CAR-NK cell engineering, examines the biological and technical challenges encountered in the clinical setting, outlines targeted preclinical approaches being implemented, and introduces recent early phase clinical trials in the pipeline. Summatively, we highlight the rapidly advancing and transformative potential of CAR-NK cell therapy for treating hematological cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014082","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:56:43Z","timestamp":1776880603000},"page":"4709-4721","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["CAR-NK cell therapy for hematological malignancies"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-7102","authenticated-orcid":false,"given":"Gohar S.","family":"Manzar","sequence":"first","affiliation":[{"name":"1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5567-262X","authenticated-orcid":false,"given":"Md Faqrul","family":"Hasan","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1814-1905","authenticated-orcid":false,"given":"Madison","family":"Moore","sequence":"additional","affiliation":[{"name":"2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"3Institute for Cell Therapy Discovery and Innovation, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2141-2365","authenticated-orcid":false,"given":"Silvia","family":"Tiberti","sequence":"additional","affiliation":[{"name":"2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"3Institute for Cell Therapy Discovery and Innovation, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-0454","authenticated-orcid":false,"given":"Rafet","family":"Basar","sequence":"additional","affiliation":[{"name":"2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"3Institute for Cell Therapy Discovery and Innovation, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6026-8397","authenticated-orcid":false,"given":"May","family":"Daher","sequence":"additional","affiliation":[{"name":"2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"3Institute for Cell Therapy Discovery and Innovation, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"10254","key":"2026071409571664700_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2026071409571664700_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"2026071409571664700_bib3","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"2026071409571664700_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"22","key":"2026071409571664700_bib5","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-generation cell therapies: the emerging role of CAR-NK cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2026071409571664700_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41392-023-01659-2","article-title":"Characteristics of premanufacture CD8(+)T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"2026071409571664700_bib7","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/bloodadvances.2022007057","article-title":"Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma","volume":"6","author":"Cuffel","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2026071409571664700_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026071409571664700_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-025-01225-9","article-title":"Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel","volume":"15","author":"Dulobdas","year":"2025","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026071409571664700_bib10","first-page":"163","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"issue":"2","key":"2026071409571664700_bib11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bjh.19939","article-title":"Advances and challenges in chimeric antigen receptor-natural killer cell immunotherapy for cancer","volume":"206","author":"Rafei","year":"2025","journal-title":"Br J Haematol"},{"issue":"8","key":"2026071409571664700_bib12","doi-asserted-by":"crossref","first-page":"e20231222","DOI":"10.1084\/jem.20231222","article-title":"Five decades of natural killer cell discovery","volume":"221","author":"Lanier","year":"2024","journal-title":"J Exp Med"},{"issue":"2","key":"2026071409571664700_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2022.09.022","article-title":"Human natural killer cells: form, function, and development","volume":"151","author":"Mace","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2026071409571664700_bib14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/2326-6066.CIR-17-0207","article-title":"Intrinsic functional potential of NK-cell subsets constrains retargeting driven by chimeric antigen receptors","volume":"6","author":"Oei","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"2026071409571664700_bib15","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2026071409571664700_bib16","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","article-title":"Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing","volume":"13","author":"Jo","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"2026071409571664700_bib17","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3324\/haematol.2019.233882","article-title":"Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: optimizing alphabeta T cell-depleted haploidentical hematopoietic stem cell transplantation","volume":"106","author":"Wiebking","year":"2021","journal-title":"Haematologica"},{"issue":"12","key":"2026071409571664700_bib18","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood.2020005185","article-title":"Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR","volume":"136","author":"Stenger","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2026071409571664700_bib19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2026071409571664700_bib20","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"2026071409571664700_bib21","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","article-title":"Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial","volume":"6","author":"Lei","year":"2025","journal-title":"Nat Cancer"},{"issue":"1","key":"2026071409571664700_bib22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov"},{"issue":"2","key":"2026071409571664700_bib23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2006.06.013","article-title":"Human NK cell education by inhibitory receptors for MHC class I","volume":"25","author":"Anfossi","year":"2006","journal-title":"Immunity"},{"issue":"4","key":"2026071409571664700_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00262-016-1792-y","article-title":"Selection and expansion of natural killer cells for NK cell-based immunotherapy","volume":"65","author":"Becker","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2026071409571664700_bib25","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2141.2009.07667.x","article-title":"Replicative potential of human natural killer cells","volume":"145","author":"Fujisaki","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"2026071409571664700_bib26","doi-asserted-by":"crossref","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"2026071409571664700_bib27","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3109\/14653249.2012.700767","article-title":"Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications","volume":"14","author":"Lapteva","year":"2012","journal-title":"Cytotherapy"},{"issue":"11","key":"2026071409571664700_bib28","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1158\/2326-6066.CIR-23-0151","article-title":"Sequential exposure to IL21 and IL15 during human natural killer cell expansion optimizes yield and function","volume":"11","author":"Zhang","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"2026071409571664700_bib29","doi-asserted-by":"crossref","first-page":"584099","DOI":"10.3389\/fimmu.2020.584099","article-title":"Cord-blood natural killer cell-based immunotherapy for cancer","volume":"11","author":"Zhao","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"2026071409571664700_bib30","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"2026071409571664700_bib31","doi-asserted-by":"crossref","first-page":"626098","DOI":"10.3389\/fimmu.2021.626098","article-title":"GMP-compliant universal antigen presenting cells (uAPC) promote the metabolic fitness and antitumor activity of armored cord blood CAR-NK cells","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"2026071409571664700_bib32","first-page":"652","article-title":"Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells","volume":"8","author":"Gong","year":"1994","journal-title":"Leukemia"},{"key":"2026071409571664700_bib33","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.3389\/fimmu.2018.02873","article-title":"Expression of a recombinant high affinity IgG Fc receptor by engineered NK cells as a docking platform for therapeutic mAbs to target cancer cells","volume":"9","author":"Snyder","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"2026071409571664700_bib34","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026071409571664700_bib35","doi-asserted-by":"crossref","first-page":"561553","DOI":"10.3389\/fimmu.2020.561553","article-title":"Umbilical cord blood and iPSC-derived natural killer cells demonstrate key differences in cytotoxic activity and KIR profiles","volume":"11","author":"Goldenson","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"2026071409571664700_bib36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13238-019-00665-x","article-title":"Functions of p53 in pluripotent stem cells","volume":"11","author":"Fu","year":"2020","journal-title":"Protein Cell"},{"issue":"12","key":"2026071409571664700_bib37","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1007\/s00262-021-02975-8","article-title":"Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors","volume":"70","author":"Khodayari","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"10473","key":"2026071409571664700_bib38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"issue":"1-2","key":"2026071409571664700_bib39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1615\/CritRevOncog.2014010931","article-title":"Clinical grade purification and expansion of natural killer cells","volume":"19","author":"Lapteva","year":"2014","journal-title":"Crit Rev Oncog"},{"issue":"5","key":"2026071409571664700_bib40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/cells13050451","article-title":"Building a better defense: expanding and improving natural killer cells for adoptive cell therapy","volume":"13","author":"Maia","year":"2024","journal-title":"Cells"},{"key":"2026071409571664700_bib41","doi-asserted-by":"crossref","first-page":"1383281","DOI":"10.3389\/fimmu.2024.1383281","article-title":"PM21-particle stimulation augmented with cytokines enhances NK cell expansion and confers memory-like characteristics with enhanced survival","volume":"15","author":"Oyer","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"2026071409571664700_bib42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/cancers13030577","article-title":"Optimizing the procedure to manufacture clinical-grade NK cells for adoptive immunotherapy","volume":"13","author":"Fernandez","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026071409571664700_bib43","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1038\/s41467-020-19094-0","article-title":"Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells","volume":"11","author":"Mark","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"2026071409571664700_bib44","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.bbmt.2014.05.004","article-title":"Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy","volume":"20","author":"Miller","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"2026071409571664700_bib45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nri2381","article-title":"Formation and function of the lytic NK-cell immunological synapse","volume":"8","author":"Orange","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"6383","key":"2026071409571664700_bib46","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.aao0505","article-title":"Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity","volume":"359","author":"Ferrari de Andrade","year":"2018","journal-title":"Science"},{"issue":"1","key":"2026071409571664700_bib47","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1038\/s41467-024-47574-0","article-title":"Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation","volume":"15","author":"Berjis","year":"2024","journal-title":"Nat Commun"},{"issue":"8","key":"2026071409571664700_bib48","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/biom14081035","article-title":"CAR-NK cell therapy: a transformative approach to overcoming oncological challenges","volume":"14","author":"Li","year":"2024","journal-title":"Biomolecules"},{"issue":"5","key":"2026071409571664700_bib49","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3390\/cells8050472","article-title":"Limitations in the design of chimeric antigen receptors for cancer therapy","volume":"8","author":"Stoiber","year":"2019","journal-title":"Cells"},{"issue":"3","key":"2026071409571664700_bib50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2026071409571664700_bib51","doi-asserted-by":"crossref","first-page":"708073","DOI":"10.3389\/fonc.2021.708073","article-title":"PSMA-specific CAR-engineered T cells for prostate cancer: CD28 outperforms combined CD28-4-1BB \u201csuper-stimulation\u201d","volume":"11","author":"Zuccolotto","year":"2021","journal-title":"Front Oncol"},{"key":"2026071409571664700_bib52","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.omtm.2021.01.008","article-title":"Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion","volume":"20","author":"Allan","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"2026071409571664700_bib53","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"issue":"21","key":"2026071409571664700_bib54","doi-asserted-by":"crossref","first-page":"eaaz3223","DOI":"10.1126\/sciadv.aaz3223","article-title":"Chimeric antigen receptor signaling: functional consequences and design implications","volume":"6","author":"Lindner","year":"2020","journal-title":"Sci Adv"},{"issue":"1","key":"2026071409571664700_bib55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","article-title":"Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy","volume":"14","author":"Gong","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2026071409571664700_bib56","doi-asserted-by":"crossref","first-page":"115122","DOI":"10.1016\/j.celrep.2024.115122","article-title":"Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells","volume":"44","author":"Melo Garcia","year":"2025","journal-title":"Cell Rep"},{"issue":"10","key":"2026071409571664700_bib57","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1158\/2159-8290.CD-24-0096","article-title":"CD28 costimulation augments CAR signaling in NK cells via the LCK\/CD3zeta\/ZAP70 signaling axis","volume":"14","author":"Acharya","year":"2024","journal-title":"Cancer Discov"},{"key":"2026071409571664700_bib58","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.3389\/fimmu.2019.03123","article-title":"High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia","volume":"10","author":"Muller","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"2026071409571664700_bib59","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00109-015-1327-6","article-title":"Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors","volume":"94","author":"Suerth","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"2026071409571664700_bib60","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.3389\/fimmu.2019.02873","article-title":"Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector","volume":"10","author":"Colamartino","year":"2019","journal-title":"Front Immunol"},{"issue":"28","key":"2026071409571664700_bib61","doi-asserted-by":"crossref","first-page":"eadn0881","DOI":"10.1126\/sciadv.adn0881","article-title":"CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer","volume":"10","author":"Tarannum","year":"2024","journal-title":"Sci Adv"},{"issue":"16","key":"2026071409571664700_bib62","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026071409571664700_bib63","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.ymthe.2024.05.022","article-title":"Engineering of potent CAR NK cells using non-viral sleeping beauty transposition from minimalistic DNA vectors","volume":"32","author":"Bexte","year":"2024","journal-title":"Mol Ther"},{"issue":"4","key":"2026071409571664700_bib64","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/2326-6066.CIR-14-0114","article-title":"Targeting CD20+ aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice","volume":"3","author":"Chu","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"2026071409571664700_bib65","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/bloodadvances.2023012463","article-title":"Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy","volume":"8","author":"Han","year":"2024","journal-title":"Blood Adv"},{"key":"2026071409571664700_bib66","doi-asserted-by":"crossref","first-page":"732135","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current perspectives on \u201coff-the-shelf\u201d allogeneic NK and CAR-NK cell therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"2026071409571664700_bib67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discov"},{"key":"2026071409571664700_bib68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"issue":"1","key":"2026071409571664700_bib69","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"20","key":"2026071409571664700_bib70","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026071409571664700_bib71","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"2026071409571664700_bib72","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"2026071409571664700_bib73","first-page":"71.e1","article-title":"Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data","volume":"31","author":"Ellithi","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"23","key":"2026071409571664700_bib74","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.2021015184","article-title":"Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia","volume":"140","author":"Cichocki","year":"2022","journal-title":"Blood"},{"issue":"30","key":"2026071409571664700_bib75","doi-asserted-by":"crossref","first-page":"eadd6997","DOI":"10.1126\/sciadv.add6997","article-title":"Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering","volume":"9","author":"Li","year":"2023","journal-title":"Sci Adv"},{"issue":"8","key":"2026071409571664700_bib76","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.ccell.2024.07.007","article-title":"Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD","volume":"42","author":"Shanley","year":"2024","journal-title":"Cancer Cell"},{"issue":"6","key":"2026071409571664700_bib77","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.cmet.2021.03.023","article-title":"Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment","volume":"33","author":"Poznanski","year":"2021","journal-title":"Cell Metab"},{"issue":"2","key":"2026071409571664700_bib78","doi-asserted-by":"crossref","first-page":"e2350635","DOI":"10.1002\/eji.202350635","article-title":"Prostaglandin E(2) impacts multiple stages of the natural killer cell antitumor immune response","volume":"54","author":"Patterson","year":"2024","journal-title":"Eur J Immunol"},{"issue":"11","key":"2026071409571664700_bib79","doi-asserted-by":"crossref","first-page":"114855","DOI":"10.1016\/j.celrep.2024.114855","article-title":"Tissue-colonizing disseminated tumor cells secrete prostaglandin E2 to promote NK cell dysfunction and evade anti-metastatic immunity","volume":"43","author":"Pedde","year":"2024","journal-title":"Cell Rep"},{"issue":"2","key":"2026071409571664700_bib80","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1158\/2326-6066.CIR-18-0481","article-title":"Lactate-mediated acidification of tumor microenvironment induces apoptosis of liver-resident NK cells in colorectal liver metastasis","volume":"7","author":"Harmon","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2026071409571664700_bib81","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4049\/jimmunol.182.1.240","article-title":"Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1","volume":"182","author":"Li","year":"2009","journal-title":"J Immunol"},{"issue":"22","key":"2026071409571664700_bib82","doi-asserted-by":"crossref","first-page":"e15722","DOI":"10.1097\/MD.0000000000015722","article-title":"CD4+CD25+Foxp3+ regulatory T cells suppress NKG2D-mediated NK cell cytotoxicity in peripheral blood","volume":"98","author":"Geng","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2026071409571664700_bib83","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fimmu.2019.00475","article-title":"Prostaglanin-E2 potentiates the suppressive functions of human mononuclear myeloid-derived suppressor cells and increases their capacity to expand IL-10-producing regulatory T cell subsets","volume":"10","author":"Tomic","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"2026071409571664700_bib84","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1189\/jlb.3A1215-552R","article-title":"M2-polarized and tumor-associated macrophages alter NK cell phenotype and function in a contact-dependent manner","volume":"101","author":"Krneta","year":"2017","journal-title":"J Leukoc Biol"},{"key":"2026071409571664700_bib85","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3389\/fimmu.2020.00311","article-title":"NK cell function regulation by TGF-beta-induced epigenetic mechanisms","volume":"11","author":"Regis","year":"2020","journal-title":"Front Immunol"},{"issue":"415","key":"2026071409571664700_bib86","doi-asserted-by":"crossref","first-page":"ra19","DOI":"10.1126\/scisignal.aad1884","article-title":"TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway","volume":"9","author":"Viel","year":"2016","journal-title":"Sci Signal"},{"issue":"2","key":"2026071409571664700_bib87","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002044","article-title":"TGFbeta drives NK cell metabolic dysfunction in human metastatic breast cancer","volume":"9","author":"Slattery","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"764","key":"2026071409571664700_bib88","doi-asserted-by":"crossref","first-page":"eadp0004","DOI":"10.1126\/scitranslmed.adp0004","article-title":"BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML","volume":"16","author":"Kumar","year":"2024","journal-title":"Sci Transl Med"},{"issue":"1","key":"2026071409571664700_bib89","doi-asserted-by":"crossref","first-page":"e0191358","DOI":"10.1371\/journal.pone.0191358","article-title":"Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models","volume":"13","author":"Otegbeye","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"2026071409571664700_bib90","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2007-07-100404","article-title":"A common pathway mediated through Toll-like receptors leads to T- and natural killer-cell immunosuppression","volume":"111","author":"Vaknin","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2026071409571664700_bib91","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/hep.23054","article-title":"Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor","volume":"50","author":"Hoechst","year":"2009","journal-title":"Hepatology"},{"issue":"24","key":"2026071409571664700_bib92","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","article-title":"Cytokine activation induces human memory-like NK cells","volume":"120","author":"Romee","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2026071409571664700_bib93","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood.2020006619","article-title":"CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas","volume":"136","author":"Gang","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2026071409571664700_bib94","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","article-title":"KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape","volume":"28","author":"Li","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"2026071409571664700_bib95","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.4049\/jimmunol.1401558","article-title":"mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function","volume":"193","author":"Donnelly","year":"2014","journal-title":"J Immunol"},{"issue":"8","key":"2026071409571664700_bib96","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ni.2936","article-title":"The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells","volume":"15","author":"Marcais","year":"2014","journal-title":"Nat Immunol"},{"key":"2026071409571664700_bib97","doi-asserted-by":"crossref","first-page":"624324","DOI":"10.3389\/fimmu.2021.624324","article-title":"Targeting SLC1A5 and SLC3A2\/SLC7A5 as a potential strategy to strengthen anti-tumor immunity in the tumor microenvironment","volume":"12","author":"Nachef","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"2026071409571664700_bib98","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ni.3470","article-title":"CIS is a potent checkpoint in NK cell-mediated tumor immunity","volume":"17","author":"Delconte","year":"2016","journal-title":"Nat Immunol"},{"issue":"2","key":"2026071409571664700_bib99","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"5","key":"2026071409571664700_bib100","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"issue":"8073","key":"2026071409571664700_bib101","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41586-025-09087-8","article-title":"CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells","volume":"643","author":"Rafei","year":"2025","journal-title":"Nature"},{"issue":"11","key":"2026071409571664700_bib102","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ni.3838","article-title":"Srebp-controlled glucose metabolism is essential for NK cell functional responses","volume":"18","author":"Assmann","year":"2017","journal-title":"Nat Immunol"},{"issue":"12","key":"2026071409571664700_bib103","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.3390\/cancers12123586","article-title":"Immunomodulatory effects of IL-2 and IL-15; implications for cancer immunotherapy","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"2026071409571664700_bib104","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/blood-2024-204369","article-title":"Mesothelin targeting IL12-engineered CAR memory-like NK cells demonstrate promising efficacy in acute myeloid leukemia","volume":"144","author":"Jang","year":"2024","journal-title":"Blood"},{"issue":"25","key":"2026071409571664700_bib105","doi-asserted-by":"crossref","first-page":"e2122379119","DOI":"10.1073\/pnas.2122379119","article-title":"Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia","volume":"119","author":"Dong","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"2026071409571664700_bib106","doi-asserted-by":"crossref","first-page":"e142116","DOI":"10.1172\/JCI142116","article-title":"Targeting the alphav integrin\/TGF-beta axis improves natural killer cell function against glioblastoma stem cells","volume":"131","author":"Shaim","year":"2021","journal-title":"J Clin Invest"},{"issue":"4","key":"2026071409571664700_bib107","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/leu.2015.327","article-title":"The TGF-beta\/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia","volume":"30","author":"Rouce","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2026071409571664700_bib108","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI123955","article-title":"Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells","volume":"129","author":"Kamiya","year":"2019","journal-title":"J Clin Invest"},{"key":"2026071409571664700_bib109","doi-asserted-by":"crossref","first-page":"1063303","DOI":"10.3389\/fimmu.2022.1063303","article-title":"Multiplexed engineering and precision gene editing in cellular immunotherapy","volume":"13","author":"Biederstadt","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"2026071409571664700_bib110","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"issue":"10","key":"2026071409571664700_bib111","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.3390\/cancers15102712","article-title":"TIGIT expression on activated NK cells correlates with greater anti-tumor activity but promotes functional decline upon lung cancer exposure: implications for adoptive cell therapy and TIGIT-targeted therapies","volume":"15","author":"Hasan","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2026071409571664700_bib112","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/2326-6066.CIR-13-0171","article-title":"Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade","volume":"2","author":"da Silva","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2026071409571664700_bib113","doi-asserted-by":"crossref","first-page":"1303605","DOI":"10.3389\/fimmu.2023.1303605","article-title":"NK cell exhaustion in the tumor microenvironment","volume":"14","author":"Jia","year":"2023","journal-title":"Front Immunol"},{"key":"2026071409571664700_bib114","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fimmu.2017.00760","article-title":"NK cell exhaustion","volume":"8","author":"Bi","year":"2017","journal-title":"Front Immunol"},{"issue":"5","key":"2026071409571664700_bib115","doi-asserted-by":"crossref","first-page":"e27196","DOI":"10.1016\/j.heliyon.2024.e27196","article-title":"CAR-NK cells in combination therapy against cancer: a potential paradigm","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"issue":"10","key":"2026071409571664700_bib116","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1089\/hum.2017.168","article-title":"Improved killing of ovarian cancer stem cells by combining a novel chimeric antigen receptor-based immunotherapy and chemotherapy","volume":"28","author":"Klapdor","year":"2017","journal-title":"Hum Gene Ther"},{"key":"2026071409571664700_bib117","doi-asserted-by":"crossref","first-page":"4263520","DOI":"10.1155\/2018\/4263520","article-title":"Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models","volume":"2018","author":"Zhang","year":"2018","journal-title":"J Immunol Res"},{"issue":"2","key":"2026071409571664700_bib118","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7150\/ijbs.65019","article-title":"Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer","volume":"18","author":"Yan","year":"2022","journal-title":"Int J Biol Sci"},{"issue":"6","key":"2026071409571664700_bib119","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","article-title":"Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial","volume":"31","author":"Nieto","year":"2025","journal-title":"Nat Med"},{"issue":"8 suppl 2","key":"2026071409571664700_bib120","doi-asserted-by":"crossref","first-page":"CT014","DOI":"10.1158\/1538-7445.AM2025-CT014","article-title":"Abstract CT014: first-in-human, multicenter study of SENTI-202, a CD33\/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic malignancies including AML: clinical data","volume":"85","author":"Strickland","year":"2025","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"2026071409571664700_bib121","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1182\/blood-2024-198684","article-title":"Safety and efficacy of FT522, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy with alloimmune defense receptor (ADR) in relapsed\/refractory B-cell lymphoma","volume":"144","author":"Bachanova","year":"2024","journal-title":"Blood"},{"key":"2026071409571664700_bib122","doi-asserted-by":"crossref","first-page":"950923","DOI":"10.3389\/fphar.2022.950923","article-title":"The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4709\/2531118\/blooda_adv-2024-014082-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4709\/2531118\/blooda_adv-2024-014082-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:57:34Z","timestamp":1784037454000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/13\/4709\/567918\/CAR-NK-cell-therapy-for-hematological-malignancies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":122,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014082","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,14]]},"published":{"date-parts":[[2026,6,30]]}}}